LOUISVILLE – October 28, 2026 -- US WorldMeds Ventures, LLC has acquired Orbus Therapeutics, Inc., adding a late-stage eflornithine program for recurrent Grade 3 astrocytoma. In a prespecified subset of the Phase 3 STELLAR study, patients with IDH-mutant disease reached median overall survival of 34.9 months, versus 23.5 months on lomustine alone.